Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome's depression treatment fails to meet main goal of late-stage study
07:18am, Tuesday, 01'st Apr 2025
Axsome Therapeutics said on Tuesday its experimental drug to treat major depressive disorder failed to meet the main goal of a late-stage study.
AXSM Stock Down Despite ADHD Study Meeting Primary Endpoint
12:55pm, Wednesday, 26'th Mar 2025
Axsome's phase III FOCUS study, evaluating solriamfetol for treating attention deficit hyperactivity disorder, meets its primary and key secondary endpoints.
Why Pharma and Biotech Stocks Got Thrashed on Tuesday
06:47pm, Tuesday, 25'th Mar 2025
As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they trad
Axsome Therapeutics' ADHD drug meets main goal in late-stage study
07:13am, Tuesday, 25'th Mar 2025
Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met the main goal in a late-stage study.
Axsome: The Alzheimer's Agitation Program For AXS-05
11:36am, Friday, 21'st Mar 2025
Axsome's AXS-05 shows strong efficacy in treating Alzheimer's Disease Agitation, with significant CMAI score reductions in multiple Phase 3 trials. The FDA has greenlit Axsome to submit an sNDA for AX
Will Auvelity & Other Drugs Aid AXSM's Growth Amid Stiff Competition?
11:56am, Friday, 14'th Mar 2025
Axsome's depression drug, Auvelity, is driving the top line while Sunosi diversifies its business. The recent FDA nod for Symbravo also bodes well.
AXSM Settles Sunosi Patent Litigation With Hikma Pharmaceuticals
11:30am, Thursday, 06'th Mar 2025
Axsome enters into a settlement agreement with Hikma Pharmaceuticals to resolve a patent litigation related to Sunosi.
AXSM Gets Positive FDA Feedback for Alzheimer's Agitation Drug Filing
02:21pm, Tuesday, 04'th Mar 2025
Based on the FDA's feedback, Axsome plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease agitation in third-quarter 2025.
On Monday, Axsome Therapeutics, Inc. AXSM announced that the EMERGE Phase 3 trial of Symbravo (MoSEIC meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
08:15am, Thursday, 20'th Feb 2025
Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering
Axsome Q4 Loss Wider Than Expected, Auvelity Drives Sales Growth
12:30pm, Tuesday, 18'th Feb 2025
AXSM's fourth-quarter 2024 earnings miss estimates while revenues beat the same. Net product sales rise year over year.
Axsome Therapeutics, Inc. (AXSM) Q4 2024 Earnings Call Transcript
11:12am, Tuesday, 18'th Feb 2025
Axsome Therapeutics, Inc. (NASDAQ:AXSM ) Q4 2024 Earnings Conference Call February 18, 2025 8:00 AM ET Company Participants Darren Opland - Director, Corporate Communications Herriot Tabuteau - Chief
Axsome Therapeutics (AXSM) Reports Q4 Loss, Tops Revenue Estimates
09:15am, Tuesday, 18'th Feb 2025
Axsome Therapeutics (AXSM) came out with a quarterly loss of $0.96 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.73 per share a year ago.
Axsome Therapeutics Revenue Surges 66%
08:06am, Tuesday, 18'th Feb 2025
Biopharmaceutical firm Axsome Therapeutics (AXSM -0.40%) reported mixed fourth-quarter and full-year 2024 earnings on Tuesday, Feb. 18. The company achieved substantial revenue growth, with sales hitt
Will These 5 Biotech Stocks Surpass Q4 Earnings Forecast?
10:30am, Monday, 17'th Feb 2025
Let's look at five biotech and drug companies, AXSM, HALO, FOLD, BMRN and INSM, slated to release their fourth-quarter 2024 results this week.
